Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases. METHODS: In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed the effect of radium-223 versus placebo on survival. An updated analysis, when 528 deaths had occurred, was performed before crossover from placebo to radium-223. RESULTS: At the interim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly improved overall survival (median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 95% confidence interval [CI], 0.55 to 0.88; two-sided P=0.002). The updated analysis involving 921 patients confirmed the radium-223 survival benefit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit of radium-233 as compared with placebo. Radium-223 was associated with low myelosuppression rates and fewer adverse events. CONCLUSIONS: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“R adiopharmaceutical therapies are gaining increasing prominence as they improve survival in patients with common diseases such as metastatic prostate cancer ( 1 , 2 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [2]
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“These are particularly substantial in the post-ARPI space, as pivotal trials of many current treatments were performed in patients who had not received a prior ARPI [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Additionally, pivotal trials of current treatments utilized conventional imaging to determine metastatic disease [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Best standard non- | ALSYMPCA Castration refractory | OS | | | 11.3 months 3.6 months | 0.70 (0.55-0.88) Improved | 5 | [68]”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“Asthenia 35 (6) 5 (1) 0 0 18 (6) 4 (1) 0 0”
InfluentialSelf-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Research works printed but not linked: 4
- Lewington VJ, 2005, J Nucl Med, 46, 38S
- Henriksen G, 2002, Cancer Res, 62, 3120
- Henriksen G, 2003, J Nucl Med, 44, 252
- Liepe K, 2009, Curr Opin Investig Drugs, 10, 1346
Cited by
Items 501–600 of 1,005
Heidenreich, A., Gillessen, S., Heinrich, D. A., Keizman, D., O’Sullivan, J. M., Carles, J., Wirth, M. P., Miller, K., Reeves, J. A., Seger, M. A., et al. (2019) · BMC Cancer · doi:10.1186/s12885-018-5203-y · Cited by 57
Self-citationTargeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer
Westaby, D., Jiménez‐Vacas, J. M., Padilha, A., Varkaris, A. S., Balk, S. P., Bono, J. S. D., & Sharp, A. (2021) · Cancers · doi:10.3390/cancers14010051 · Cited by 67
Martori, C., Sánchez-Moral, L., Paul, T., Pardo, J. C., Pous, A. F., de Porras, V. R., & Sarrias, M. (2022) · Cancers · doi:10.3390/cancers14020440 · Cited by 53
“However, over the last ten years the therapeutic landscape of mCRPC has changed dramatically [6] thanks to the discovery and subsequent approval of the second-generation taxane cabazitaxel [7], new androgen receptor signaling inhibitors (ARSIs) such as abiraterone [8,9] and enzalutamide [10], the alpha-emitter radium-…”
BackgroundMcNeel, D. G., Gardner, T. A., Higano, C. S., Kantoff, P. W., Small, E. J., Wener, M. H., Sims, R. B., DeVries, T. A., Sheikh, N. A., & Dreicer, R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0073 · Cited by 53
Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223
Coleman, R. E. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.10.012 · Cited by 51
Self-citationGiovacchini, G., Giovannini, E., Leoncini, R., Riondato, M., & Ciarmiello, A. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3700-x · Cited by 56
“Even though some tracers had the favorable capability of being suitable both for diagnostic and for therapeutic purposes, clinical applications have always been limited partly due to more available and more efficacious diagnostic and therapeutic compounds [190, 191].”
BackgroundWong, W. W., Anderson, E. M., Mohammadi, H., Daniels, T. B., Schild, S. E., Keole, S. R., Choo, C. R., Tzou, K. S., Bryce, A. H., Ho, T. H., et al. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.04.016 · Cited by 51
“In the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) study, patients with mCRPC were randomized to (223)Ra or placebo.(3) There was a significant improvement in median survival of 3.”
MethodTargeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response
Malcolm, J., Falzone, N., Lee, B. Q., & Vallis, K. A. (2019) · Cancers · doi:10.3390/cancers11020268 · Cited by 56
Turco, F., Gillessen, S., Cathomas, R. L., Buttigliero, C., & Vogl, U. M. (2022) · Research and Reports in Urology · doi:10.2147/rru.s360444 · Cited by 58
Pan, E., Xie, W., Ajmera, A., Araneta, A., Jamieson, C., Folefac, E., Hussain, A., Kyriakopoulos, C. E., Olson, A. C., Parikh, M., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0583 · Cited by 53
Hoefeler, H., Duran, I., Hechmati, G., Garzon Rodriguez, C., Lüftner, D., Ashcroft, J., Bahl, A., Atchison, C., Wei, R., Thomas, E., et al. (2014) · Journal of Bone Oncology · doi:10.1016/j.jbo.2014.04.001 · Cited by 50
Nanoparticle Therapy for Prostate Cancer: Overview and Perspectives
Zhang, J., Wang, L., You, X., Xian, T., Wu, J., & Pang, J. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190125145836 · Cited by 55
Feijtel, D., Doeswijk, G. N., Verkaik, N. S., Haeck, J. C., Chicco, D., Angotti, C., Konijnenberg, M., de Jong, M., & Nonnekens, J. (2020) · Theranostics · doi:10.7150/thno.51215 · Cited by 55
“Increasing the therapeutic efficacy might be accomplished by changing the treatment planning (time interval or dosing), by developing new targeting biomolecules [7, 8], by using more powerful radionuclides [9] or by combining PRRT with other treatments, such as DNA damage repair modulating compounds [10].”
BackgroundProstate cancer bone metastases biology and clinical management (Review)
Goode, E. A., Wang, N., & Munkley, J. (2023) · Oncology Letters · doi:10.3892/ol.2023.13749 · Cited by 63
Nilsson, S. F. (2016) · Current Oncology Reports · doi:10.1007/s11912-015-0495-4 · Cited by 53
Self-citationConteduca, V., Crabb, S. J., Jones, R. J., Caffo, O., Elliott, T., Scarpi, E., Fabbri, P., Derosa, L., Massari, F., Numico, G., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158952 · Cited by 52
Uemura, H., Matsubara, N., Kimura, G., Yamaguchi, A., Ledesma, D. A., DiBonaventura, M., Mohamed, A. F., Basurto, E., McKinnon, I., Wang, E., et al. (2016) · BMC Urology · doi:10.1186/s12894-016-0182-2 · Cited by 53
Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer
Lorente, D., Fizazi, K. S., Sweeney, C. J., & Bono, J. S. D. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.10.008 · Cited by 54
Castello, A., Macapinlac, H. A., Lopci, E., & Santos, E. B. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4051-y · Cited by 49
Deblonde, G. J. ‐., Lohrey, T. D., Booth, C. H., Carter, K. P., Parker, B. F., Larsen, Å., Smeets, R., Ryan, O. B., Cuthbertson, A., & Abergel, R. J. (2018) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.8b02430 · Cited by 50
Meyrick, D. P., Gallyamov, M., Sabarimurugan, S., Falzone, N., & Lenzo, N. P. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00801-w · Cited by 58
Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography
Oprea‐Lager, D. E., Cysouw, M. C. F., Boellaard, R., Deroose, C. M., de Geus‐Oei, L., Lopci, E., Bidaut, L. M., Herrmann, K., Fournier, L. S., Bäuerle, T., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.772530 · Cited by 55
“Treatment with Radium-223, a calcium-mimetic and alphaemitter that selectively binds to areas of increased bone turnover, results in significantly prolonged OS in patients who had castration-resistant prostate cancer and bone metastases (30).”
BackgroundThe best of both worlds — managing the cancer, saving the bone
Makhoul, I., Montgomery, C. O., Gaddy, D., & Suva, L. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.185 · Cited by 53
Sonpavde, G., Bhor, M., Hennessy, D., Bhowmik, D., Shen, L., Nicacio, L., Rembert, D., Yap, M., & Schnadig, I. D. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2014.12.019 · Cited by 52
Armstrong, A. J., Kaboteh, R., Carducci, M. A., Damber, J. ‐., Stadler, W. M., Hansen, M., Edenbrandt, L., Forsberg, G., Nordle, Ö., Пили, Р., et al. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.08.006 · Cited by 48
Current and Emerging Therapies for Bone Metastatic Castration-Resistant Prostate Cancer
Frieling, J. S., Basanta, D., & Lynch, C. C. (2015) · Cancer Control · doi:10.1177/107327481502200114 · Cited by 55
Ramalingam, S., Ramamurthy, V. P., & Njar, V. C. O. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.07.006 · Cited by 57
Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy
McKay, R. R., Jacobus, S. J., Fiorillo, M., Ledet, E. M., Cotogna, P. M., Steinberger, A. E., Jacene, H. A., Sartor, O. A., & Taplin, M. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.08.015 · Cited by 48
“The efficacy of radium-223 in mCRPC was demonstrated in the ALSYMPCA (Alpharadin in Symptomatic Prostate Cancer) trial.(3) This phase III, doubleblinded trial randomized 922 men with mCRPC with bone metastases who had received previous docetaxel treatment or were”
MethodSelf-citationCost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
Pollard, M. E., Moskowitz, A. J., Diefenbach, M. A., & Hall, S. J. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.11.005 · Cited by 54
Treatment of Bone Metastasis with Bone-Targeting Radiopharmaceuticals
Choi, J. Y. (2018) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-017-0509-2 · Cited by 48
Hendriks, R. J., Dijkstra, S., Smit, F. P., Vandersmissen, J., de Voorde, H. V., Mulders, P., van Oort, I. M., Criekinge, W. V., & Schalken, J. A. (2018) · The Prostate · doi:10.1002/pros.23477 · Cited by 48
“APC (evaluable samples) Copies (median [IQR]) 37 (79%) 59 (14-138) 25 (56%) 31 (12-172) 26 (74%) 26 (5-88) 24 (96%) 50 (13-183) 3 (43%) 12 (10-12) P < 0.”
Targeted alpha therapy using Radium-223: From physics to biological effects
Marques, I. A., Neves, R., Abrantes, A. M., Pires, A. S., Tavares-da-Silva, E., Figueiredo, A., & Botelho, M. F. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.05.011 · Cited by 50
Briot, K., Paccou, J., Beuzeboc, P., Bonneterre, J. M., Bouvard, B., Confavreux, C. B., Cormier, C., Cortet, B., Hannoun‐Lévi, J., Hennequin, C., et al. (2018) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.09.017 · Cited by 50
Gafita, A., Rauscher, I., Retz, M. M., Knorr, K., Heck, M. M., Wester, H., D’Alessandria, C., Weber, W., Eiber, M., & Tauber, R. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.215715 · Cited by 52
“8 mo) for 3-weekly 25 mg/m2 cabazitaxel, 223Ra, and our small cohort of 177Lu-PSMA-I&T rechallenge, respectively (11,12).”
BackgroundDizdarevic, S., Petersen, R. H., Essler, M., Versari, A., Bourre, J. C., la Fougère, C. J., Valdagni, R., Paganelli, G., Ezziddin, S., Kalinovský, J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-4261-y · Cited by 48
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial
Subbiah, V., Anderson, P. M., Kairemo, K., Hess, K. R., Huh, W. W., Ravi, V., Daw, N. C., Somaiah, N., Ludwig, J. A., Benjamin, R. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3964 · Cited by 50
“Radium 223 dichloride ((223)RaCl2), developed by yvind Bruland at the Norwegian Radium Hospital in Oslo, Norway, is an alpha-emitting radiopharmaceutical and calcimimetic with intrinsic bone-targeting properties (6–9) and has received FDA and European Medicines Agency approval for castration-resistant prostate cancerw…”
BackgroundLadjohounlou, R., Lozza, C., Pichard, A., Constanzo, J., Karam, J., Fur, P. L., Deshayes, E., Boudousq, V., Paillas, S., Busson, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3295 · Cited by 56
“This is even more marked when radionuclides used in clinical trials emit high linear energy transfer (high-LET) particles, namely alpha particles or Auger electrons (3, 5, 6, 28).”
BackgroundRadiobiological effects of the alpha emitter Ra-223 on tumor cells
Bannik, K., Madas, B. G., Jarzombek, M., Sutter, A. P., Siemeister, G., Mumberg, D., & Zitzmann-Kolbe, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-54884-7 · Cited by 53
Kanesvaran, R., Castro, E., Wong, A. S. C., Fizazi, K. S., Chua, M. L. K., Zhu, Y., Malhotra, H., Miura, Y., Lee, J. L., Chong, F. L. T., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100518 · Cited by 51
“83) in patients with symptomatic, bone-predominant mCRPC.(119) In Japan, a study of Ra-223, in a real-life setting, showed Ra-223 to be well tolerated in all groups.”
BackgroundKairemo, K., & Joensuu, T. K. (2015) · Diagnostics · doi:10.3390/diagnostics5040413 · Cited by 48
Ahaghotu, C. A., Tyler, R. C., & Sartor, O. A. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2015.12.003 · Cited by 51
Self-citationKeizman, D., Fosbøl, M. Ø., Reichegger, H., Peer, A., Rosenbaum, E., Desax, M.-C., Neiman, V., Petersen, R. H., Mueller, J., Cathomas, R. L., et al. (2017) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2017.6 · Cited by 47
Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases
Mohme, M., Riethdorf, S., Dreimann, M., Werner, S., Maire, C. L., Joosse, S. A., Bludau, F., Müller, V., Neves, R. P., Stoecklein, N. H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07649-z · Cited by 47
Nordstrand, A., Ylitalo, E. B., Thysell, E., Jernberg, E., Crnalic, S., Widmark, A., Bergh, A. R. J., Lerner, U. H., & Wikström, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041223 · Cited by 67
“Patients with non-AR driven metastatic disease have few treatment options, but might benefit from therapies targeting the tumor microenvironment such as immunotherapy, bisphosphonates, receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors, or radioisotopes [23,24].”
BackgroundSelf-citationAtomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management
Roscher, M., Bakos, G., & Benešová, M. (2020) · Pharmaceuticals · doi:10.3390/ph13040076 · Cited by 53
Ailanthone: A novel potential drug for treating human cancer (Review)
Ding, H., Yu, X., Chen, H., Gao, K., Lao, X., Jia, Y., & Yan, Z. (2020) · Oncology Letters · doi:10.3892/ol.2020.11710 · Cited by 53
“The drugs currently used in CRPC are docetaxel (83), cabazitaxel (84), abiraterone (85), radium‐223 (86) and enzalutamide (87).”
BackgroundRadionuclide Therapy in Prostate Cancer: From Standalone to Combination PSMA Theranostics
Sandhu, S. K., Guo, C. W., & Hofman, M. S. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.243295 · Cited by 53
“(223)Ra-dichloride showed an OS benefit and a reduced time to the first symptomatic skeletal event in patients with mCRPC involving bone (16).”
BackgroundNew Approaches in Radiotherapy
Webster, M. J., Podgorsak, A. R., Li, F., Zhou, Y., Jung, H., Yoon, J., Lemus, O. D., & Zheng, D. (2025) · Cancers · doi:10.3390/cancers17121980 · Cited by 61
Current clinical challenges in prostate cancer.
Silberstein, J. L., Pal, S. K., Lewis, B. E., & Sartor, O. A. (2013) · PubMed Central · doi:10.3978/j.issn.2223-4683.2013.09.03 · Cited by 66
Self-citationNew cancer therapies and jaw necrosis
Patel, V., Kelleher, M., Sproat, C., Kwok, J., & McGurk, M. (2015) · BDJ · doi:10.1038/sj.bdj.2015.680 · Cited by 50
Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer
Roubaud, G., Liaw, B. C.-H., Oh, W. K., & Mulholland, D. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.181 · Cited by 50
Alva, A. S., Nordquist, L. T., Daignault, S. D., George, S., Ramos, J., Albany, C., Isharwal, S., McDonald, M. J., Campbell, G. D., Danchaivijitr, P., et al. (2016) · The Prostate · doi:10.1002/pros.23286 · Cited by 47
Diagnostic characteristics of lethal prostate cancer
Helgstrand, J. T., Røder, M. A., Klemann, N., Toft, B. G., Brasso, K., Vainer, B., & Iversen, P. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.007 · Cited by 49
Fosbøl, M. Ø., Petersen, R. H., Kjær, A., & Mortensen, J. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.195677 · Cited by 46
“Radionuclide therapy with the a-emitting (223)RaCl2 prolongs life and time to symptomatic skeletal events in patients with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases (1,2).”
BackgroundBrodowicz, T., Hadji, P., Niepel, D., & Diel, I. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.008 · Cited by 49
Saad, F., Sternberg, C. N., Mulders, P., Niepel, D., & TOMBAL, B. F. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.014 · Cited by 49
“New therapies have changed the face of mCRPC treatment, improving survival and pain control, and having a positive effect on the bone health of patients [6,35,36,41,42].”
BackgroundInfluentialTargeted Palliative Radionuclide Therapy for Metastatic Bone Pain
Manafi‐Farid, R., Masoumi, F., Divband, G., Saidi, B., Ataeinia, B., Hertel, F., Schweighofer-Zwink, G., Morgenroth, A., & Beheshti, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082622 · Cited by 51
“Also, significantly improved quality of life and higher pain relief, as well as longer time to first symptomatic SRE, need for EBRT and initial opioid use have been demonstrated [120,121] [35,121,122].”
BackgroundClinical Perspectives of Theranostics
Okamoto, S., Shiga, T., & Tamaki, N. (2021) · Molecules · doi:10.3390/molecules26082232 · Cited by 51
“Malignant pheochromocytoma, Paraganglioma Norepinephrine transporter I-123 MIBGI-131 MIBG I-131 MIBG [11,12] Neuroendocrine tumor Somatostatine receptor In-111 Pentetreotide Ga-68 DOTATE Ga-68 DOTATOC Lu-177 DOTATATE [13] Lu-177 DOTATOC Y-90 DOTATATE Y-90 DOTATOC B-cell non-Hodgkin malignant lymphoma Anti-CD20 recepto…”
BackgroundInfluentialDevelopments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment
Kerr, C. P., Grudzinski, J. J., Nguyen, T. P., Hernandez, R. T., Weichert, J. P., & Morris, Z. S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010128 · Cited by 51
“Despite positive Phase III results of Xofigo® monotherapy [24], early investigations of (223)RaCl2 combination therapy have not demonstrated a therapeutic benefit.”
BackgroundHope, T. A., Antonarakis, E. S., Bodei, L., Calais, J., Iravani, A., Jacene, H. A., Koo, P. J., Morgans, A. K., Osborne, J. R., Tagawa, S. T., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265952 · Cited by 56
“In the ALSYMPCA trial, patients with mCRPC had an OS benefit from radium-223 compared with the best standard of care (8).”
BackgroundSelf-citationAzad, A., Eigl, B. J., Leibowitz‐Amit, R., Lester, R. E., Kollmannsberger, C., Murray, N., Clayton, R., Heng, D. Y. C., Joshua, A. M., & Chi, K. N. (2014) · European Urology · doi:10.1016/j.eururo.2014.01.030 · Cited by 45
Obara, W., Sato, F., Takeda, K., Kato, R., Kato, Y., Kanehira, M., Takata, R., Mimata, H., Sugai, T., Nakamura, Y., et al. (2017) · Cancer Science · doi:10.1111/cas.13278 · Cited by 49
Bone-targeted Cabazitaxel Nanoparticles for Metastatic Prostate Cancer Skeletal Lesions and Pain
Gdowski, A., Ranjan, A. P., Sarker, M. R., & Vishwanatha, J. K. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0190 · Cited by 45
Uemura, K., Kawahara, T., Yamashita, D., Jikuya, R., Abe, K., Tatenuma, T., Yokomizo, Y., Izumi, K., Teranishi, J., Makiyama, K., et al. (2017) · BioMed Research International · doi:10.1155/2017/7538647 · Cited by 46
Apalutamide for the treatment of prostate cancer
Rathkopf, D. E., & Scher, H. I. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1503954 · Cited by 48
Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments
Farolfi, A., Fendler, W. P., Iravani, A., Haberkorn, U., Hicks, R. J., Herrmann, K., Walz, J. C., & Fanti, S. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.01.001 · Cited by 47
Prostate Cancer Brain Metastases: A Single-Institution Experience
Bhambhvani, H. P., Greenberg, D. R., Srinivas, S., & Gephart, M. H. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.02.152 · Cited by 49
Dorff, T. B., Hirasawa, Y., Acoba, J. D., Pagano, I., Tamura, D. J., Pal, S. K., Zhang, M., Waitz, R., Dhal, A., Haynes, W. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002931 · Cited by 52
Capturing an elusive but critical element: Natural protein enables actinium chemistry
Deblonde, G. J. ‐., Mattocks, J. A., Dong, Z., Wooddy, P. T., Cotruvo, J. A., & Zavarin, M. (2021) · Science Advances · doi:10.1126/sciadv.abk0273 · Cited by 44
Rosar, F., Wenner, F. N., Khreish, F., Dewes, S., Wagenpfeil, G., Hoffmann, M. A., Schreckenberger, M., Bartholomä, M. D., & Ezziddin, S. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05594-8 · Cited by 47
Disparities in germline testing among racial minorities with prostate cancer
Weise, N., Shaya, J. A., Javier-DesLoges, J. F., Cheng, H. H., Madlensky, L., & McKay, R. R. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00469-3 · Cited by 50
“ALSYMPCA—Radium-223 [82] 921 865 NR NR NR NR NR NR”
BackgroundHj, B., Ezziddin, S., & Knapp, F. F. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1310231 · Cited by 45
Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities
Kumari, S., Sharma, V., Tiwari, R., Maurya, J. P., Subudhi, B. B., & Senapati, D. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174807 · Cited by 52
Choudhury, A. D., Kwak, L., Cheung, A., Allaire, K. M., Marquez, J., Yang, D. D., Tripathi, A., Kilar, J. M., Flynn, M., Maynard, B., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0306 · Cited by 53
“Strati fi cationfactorswere alkaline phosphatase ≥ 220 versus 220 U/L [as in the phase III ALSYMPCA trial of radium-223 (21)] and high versus low volume bony metastases by CHAARTED criteria (22).”
BackgroundSequencing current therapies in the treatment of metastatic prostate cancer
Valença, L. B., Sweeney, C. J., & Pomerantz, M. M. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.02.010 · Cited by 48
Targeted alpha anticancer therapies: update and future prospects
Allen, B., Huang, C., & Clarke, R. A. (2014) · Biologics · doi:10.2147/btt.s29947 · Cited by 53
A Radium-223 microgenerator from cyclotron-produced trace Actinium-227
Abou, D. S., Pickett, J., Mattson, J. E., & Thorek, D. L. J. (2016) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2016.10.015 · Cited by 47
Alibhai, S. M. H., Zukotynski, K., Walker‐Dilks, C., Emmenegger, U., Finelli, A., Morgan, S. C., Hotte, S. J., & Winquist, E. (2017) · Clinical Oncology · doi:10.1016/j.clon.2017.01.007 · Cited by 44
Leung, C. N., Canter, B. S., Rajon, D. A., Bäck, T. A., Fritton, J. C., Azzam, E. I., & Howell, R. W. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.227835 · Cited by 46
“Patients given (223)RaCl2 demonstrated decreases in bone pain and, unlike previous bone-metastatic palliative radiotherapies such as the b-emitting 89Sr, increased survival (1).”
BackgroundGeorge, D. J., Halabi, S., Heath, E. I., Sartor, O. A., Sonpavde, G., Das, D. G., Bitting, R. L., Berry, W. R., Healy, P. N., Anand, M., et al. (2021) · Cancer · doi:10.1002/cncr.33589 · Cited by 46
Self-citationRobinson, A. G., Booth, C. M., & Eisenhauer, E. A. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.05.024 · Cited by 45
Benabdallah, N., Scheve, W., Dunn, N., Silvestros, D., Schelker, P., Abou, D. S., Jammalamadaka, U. M., Laforest, R. A., Li, Z., Liu, J., et al. (2021) · Theranostics · doi:10.7150/thno.63860 · Cited by 46
“The efficacy of 223Ra in mCRPC patients has been demonstrated in multiple studies [2-11] and this radionuclide has three principal gamma emissions at 81, 154, and 270 keV [12].”
BackgroundRadiopharmaceuticals heat anti-tumor immunity
Sun, Q., Li, J., Ding, Z., & Liu, Z. (2023) · Theranostics · doi:10.7150/thno.79806 · Cited by 45
“223Ra is a calcium mimetic and naturally targets the bone hydroxyapatite (Ca10(PO4)6(OH)2) matrix [67-70].”
Advances in Radioligand Theranostics in Oncology
Lawal, I. O., Abubakar, S., Ndlovu, H., Mokoala, K. M. G., More, S. S., & Sathekge, M. M. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00702-4 · Cited by 49
“223 RaCl 2 and 177 Lu-PSMA-617, in phase 3 clinical trials, demonstrated survival benefits for mCRPC patients compared with standard-of-care therapy options [82, 83].”
Lee, Y.-C., Lin, S.-C., Yu, G., Cheng, C.-J., Liu, B., Liu, H., Hawke, D. H., Parikh, N. U., Varkaris, A. S., Corn, P. G., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1215 · Cited by 43
Treatment sequencing in metastatic castrate-resistant prostate cancer
Sartor, O. A., & Gillessen, S. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.126378 · Cited by 45
Self-citationProstate Cancer and Bone: The Elective Affinities
Rucci, N., & Angelucci, A. (2014) · BioMed Research International · doi:10.1155/2014/167035 · Cited by 50
Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer
Hoang, B., Ernsting, M. J., Tang, W.-H. S., Bteich, J., Undzys, E., Kiyota, T., & Li, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.029 · Cited by 44
Rathke, H. G., Afshar‐Oromieh, A., Giesel, F. L., Kremer, C., Flechsig, P., Haufe, S., Mier, W., Holland‐Letz, T., de Bucourt, M., Armor, T., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200220 · Cited by 43
“The diagnosis of visceral metastases is important for prognosis and treatment stratification, as visceral metastases or lymph nodes of greater than 3 cm prohibit the application of (223)RaCl2 and necessitate another therapeutic strategy (31).”
BackgroundMiyahira, A. K., Pienta, K. J., Morris, M. J., Bander, N. H., Baum, R. P., Fendler, W. P., Goeckeler, W. F., Gorin, M. A., Hennekes, H., Pomper, M. G., et al. (2018) · The Prostate · doi:10.1002/pros.23642 · Cited by 44
“FDA in 2013.(15) These studies, along with the initial clinical experiences with several hundreds of patients treated with various”
BackgroundSelf-citationŠimeček, J., Hermann, P., Seidl, C., Bruchertseifer, F., Morgenstern, A., Wester, H., & Notni, J. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0431-3 · Cited by 45
“The recent approval and market entry of (223)Ra chloride as an α-emitting therapeutic radiopharmaceutical [4] and successful application of (225)Ac-labeled inhibitors of prostate-specific membrane antigen (PSMA) for treatment of prostate cancer [5] highlighted the clinical potential of α-therapy and led to a tremendou…”
BackgroundIorio, G. C., Spieler, B. O., Ricardi, U., & Pra, A. D. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103497 · Cited by 49
Mitsogiannis, I. C., Tzelves, L. I., Dellis, A., Issa, H., Papatsoris, A., & Moussa, M. J. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2027904 · Cited by 50
Persson, M., Juhl, K., Rasmussen, P., Brandt-Larsen, M., Madsen, J., Ploug, M., & Kjær, A. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500177c · Cited by 44
Patrick, D. L., Cleeland, C. S., von Moos, R., Fallowfield, L. J., Wei, R., Öhrling, K., & Qian, Y. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2525-4 · Cited by 49
Nome, R. V., Hernes, E., Bogsrud, T. V., Bjøro, T., & Fosså, S. D. (2014) · Scandinavian Journal of Urology · doi:10.3109/21681805.2014.982169 · Cited by 42
Self-citationPosadas, E. M., Ahmed, R. S., Karrison, T. G., Szmulewitz, R. Z., O’Donnell, P. H., Wade, J. L., Shen, J., Gururajan, M., Sievert, M. F., & Stadler, W. M. (2015) · The Prostate · doi:10.1002/pros.23119 · Cited by 44
Radium-223 dichloride in clinical practice: a review
Florimonte, L., Dellavedova, L., & Maffioli, L. S. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3386-5 · Cited by 46
Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?
Casimiro, S., Ferreira, A. R., Mansinho, A., Alho, I., & Costa, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091415 · Cited by 49
The molecular underpinnings of prostate cancer: impacts on management and pathology practice
Rodrigues, D. N., Boysen, G., Sumanasuriya, S., Seed, G., Marzo, A. M. D., & Bono, J. S. D. (2016) · The Journal of Pathology · doi:10.1002/path.4826 · Cited by 43
Metadata
- Authors
- Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D. C., Hoskin, P., Bottomley, D., James, N. D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall'Oglio, M., Franzén, L., Coleman, R., Vogelzang, N. J., O'Bryan-Tear, C. G., Staudacher, K., Garcia-Vargas, J., Shan, M., Bruland, Ø. S., & Sartor, O.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 213-223
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141454098
- Cited by
- 3,408
- References
- 36
- Citations by year
- 2026: 162 · 2025: 213 · 2024: 230 · 2023: 252 · 2022: 253 · 2021: 307 · 2020: 274 · 2019: 268 · 2018: 321 · 2017: 279 · 2016: 288 · 2015: 253 · 2014: 250 · 2013: 50
- FWCI
- 228.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- radium-223 dichloride, alpha-emitting radiopharmaceuticals, castration-resistant prostate cancer, bone metastasis, overall survival, skeletal-related events, docetaxel, myelosuppression, treatment safety, ALSYMPCA trial, interim analysis
- MeSH terms
- Aged, Aged, 80 and over, Bone Neoplasms, Double-Blind Method, Humans, Isotopes, Male, Middle Aged, Prostatic Neoplasms, Radium, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.